Stryker (SYK) Competitors

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.9%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Cardinal Health pays out 31.5% of its earnings in the form of a dividend. Stryker pays out 40.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years and Stryker has raised its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.1% of Cardinal Health shares are owned by company insiders. Comparatively, 4.6% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cardinal Health has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Stryker has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Cardinal Health presently has a consensus target price of $249.13, suggesting a potential upside of 5.77%. Stryker has a consensus target price of $392.87, suggesting a potential upside of 19.10%. Given Stryker's higher possible upside, analysts clearly believe Stryker is more favorable than Cardinal Health.

Stryker has a net margin of 13.20% compared to Cardinal Health's net margin of 0.62%. Stryker's return on equity of 23.42% beat Cardinal Health's return on equity.

In the previous week, Stryker had 18 more articles in the media than Cardinal Health. MarketBeat recorded 23 mentions for Stryker and 5 mentions for Cardinal Health. Stryker's average media sentiment score of 1.33 beat Cardinal Health's score of 0.41 indicating that Stryker is being referred to more favorably in the news media.

Stryker has lower revenue, but higher earnings than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 97.5% of Cencora shares are owned by institutional investors. 4.6% of Stryker shares are owned by insiders. Comparatively, 0.4% of Cencora shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Stryker has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Cencora has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Stryker has higher earnings, but lower revenue than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker presently has a consensus target price of $392.87, suggesting a potential upside of 19.10%. Cencora has a consensus target price of $367.75, suggesting a potential upside of 21.24%. Given Cencora's higher possible upside, analysts clearly believe Cencora is more favorable than Stryker.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.8%. Stryker pays out 40.7% of its earnings in the form of a dividend. Cencora pays out 18.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and Cencora has raised its dividend for 15 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has a net margin of 13.20% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Stryker's return on equity.

In the previous week, Stryker had 15 more articles in the media than Cencora. MarketBeat recorded 23 mentions for Stryker and 8 mentions for Cencora. Cencora's average media sentiment score of 1.64 beat Stryker's score of 1.33 indicating that Cencora is being referred to more favorably in the news media.

In the previous week, Stryker had 16 more articles in the media than DaVita. MarketBeat recorded 23 mentions for Stryker and 7 mentions for DaVita. Stryker's average media sentiment score of 1.33 beat DaVita's score of 0.56 indicating that Stryker is being referred to more favorably in the media.

Stryker currently has a consensus price target of $392.87, suggesting a potential upside of 19.10%. DaVita has a consensus price target of $209.00, suggesting a potential downside of 10.11%. Given Stryker's stronger consensus rating and higher probable upside, analysts clearly believe Stryker is more favorable than DaVita.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, DaVita has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

77.1% of Stryker shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 1.5% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Stryker has a net margin of 13.20% compared to DaVita's net margin of 5.65%. Stryker's return on equity of 23.42% beat DaVita's return on equity.

Medtronic has higher revenue and earnings than Stryker. Medtronic is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

82.1% of Medtronic shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.3% of Medtronic shares are owned by company insiders. Comparatively, 4.6% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medtronic has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Stryker has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.4%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Stryker pays out 40.7% of its earnings in the form of a dividend. Medtronic has increased its dividend for 49 consecutive years and Stryker has increased its dividend for 32 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Medtronic had 5 more articles in the media than Stryker. MarketBeat recorded 28 mentions for Medtronic and 23 mentions for Stryker. Stryker's average media sentiment score of 1.33 beat Medtronic's score of 1.14 indicating that Stryker is being referred to more favorably in the news media.

Medtronic presently has a consensus target price of $98.17, indicating a potential upside of 17.18%. Stryker has a consensus target price of $392.87, indicating a potential upside of 19.10%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than Medtronic.

Stryker's return on equity of 23.42% beat Medtronic's return on equity.